KeyNeurotek Pharmaceuticals

KeyNeurotek Pharmaceuticals was a clinical-stage biotechnology company based in Magdeburg, Germany, focused on developing innovative therapies for degenerative and traumatic disorders of the central nervous system. The company's research centered on neuroprotection and neuroregeneration, particularly for indications such as traumatic brain injury, stroke, and neuropathic pain. Its lead program, KN-387, was a small molecule NMDA receptor antagonist that reached Phase 2 clinical trials. KeyNeurotek utilized its proprietary KeyScreen platform to identify compounds that could prevent neuronal cell death. In 2012, the company was acquired by Bionorica SE, a leading German manufacturer of herbal medicines, to integrate KeyNeurotek's CNS expertise into its pharmaceutical portfolio.